Month: June 2021

BEVERLY, Mass., June 28, 2021 (GLOBE NEWSWIRE) — LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG), (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce it has retained LaVoieHealthScience (LHS) as its investor and public relations (IR and PR) agency of record. LHS will work side-by-side with LexaGene’s senior management, marketing, and financial teams to implement a comprehensive suite of IR and PR services and counsel to help the Company gain visibility among the investment community, as it charts a course toward a potential up-listing to the Nasdaq Stock Market in the United States. LHS is a strategic, integrated communications firm with a keen focus on helping life science and medical technology companies solve complex communications challenges....

GREENWICH, Conn., June 28, 2021 (GLOBE NEWSWIRE) — XPO Logistics, Inc. (“XPO” or the “company”) (NYSE: XPO) today announced that it plans to make a registered underwritten offering of 5 million shares of its common stock consisting of an equal number of shares to be offered by XPO and by Jacobs Private Equity, LLC, the selling stockholder and an affiliate of Brad Jacobs, XPO’s chairman and chief executive officer. XPO and the selling stockholder expect to grant the underwriters a 30-day option to purchase up to an aggregate of 750,000 additional shares, which additional shares will also be split equally between XPO and the selling stockholder. XPO expects to use the net proceeds from this offering to repay a portion of the company’s outstanding borrowings and for general corporate purposes. XPO will not receive any proceeds from...

                 28 June 2021Announcement no. 323 Financial Calendar 2021/22 10 September 2021, Annual Report 2020/21 25 October 2021, Annual General Meeting in Rovsing A/S 15 November 2021, Interim Management Statement Q1 2021/22 21 February 2022, Interim Report for H1 2021/22 16 May 2022, Interim Management Statement for Q3 2021/22 9 September 2022, Annual Report 2021/22 24 October 2022, Annual General Meeting in Rovsing A/SFor further information Rovsing A/S, Hjalti Pall Thorvardarson, CEO; e-mail: hpt@rovsing.dkAttachmentAnnouncement323_Financial_Calender

Largest non-portfolio Single Asset, Single Borrower CMBS securitization in history NEW YORK, June 28, 2021 (GLOBE NEWSWIRE) — SL Green Realty Corp (NYSE: SLG), Manhattan’s largest office landlord, today announced that it has closed a $3.0 billion 10-year, fixed-rate financing of One Vanderbilt Avenue, the skyline-defining tower in the heart of East Midtown, which is owned in a joint venture between SL Green, National Pension Service of Korea and Hines Interests, LP. The loan was securitized in a single asset, single borrower (SASB) agented CMBS transaction. The agents were a consortium of world class financial institutions, led by Wells Fargo Bank, N.A. and Goldman Sachs Bank USA, that also included Bank of America N.A., Bank of China, Bank of Montreal, Deutsche Bank, JP Morgan Chase Bank, N.A., Barclays Capital Real Estate Inc....

Current CEO to assume role of Executive Chairman TORONTO, June 28, 2021 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that it has appointed Dr. Neil Maresky as Chief Executive Officer. Dr. Maresky joins Psyence after just having  completed more than a decade at AstraZeneca Canada, most recently as Vice President of Scientific Affairs. Co-founder and current Chief Executive Officer Jody Aufrichtig will assume the role of Executive Chairman with immediate effect. Dr. Maresky brings more than 20 years of enterprise leadership and biopharmaceutical expertise to this role. He will oversee the strategy and operations of Psyence and ensure the delivery of key metrics...

DURHAM, N.C., June 28, 2021 (GLOBE NEWSWIRE) — Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that it has been added to the Russell Microcap® Index, following the annual Russell indexes reconstitution, effective after the US market opens today, June 28, 2021, according to a final list of additions posted on June 25, 2021. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in Russell’s appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes. Jeff Wolf, Chief Executive Officer of Heat, commented, “We are extremely pleased to...

Preliminary data demonstrates robust performance on nanopore sequencing Accuracy of 100% for pathogen identification and up to 97% for AMR markers and up to 100% on predicting ASTROCKVILLE, Md., June 28, 2021 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, today announced that its subsidiary Ares Genetics, which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance (AMR), presented an update on the company’s R&D pipeline during two virtual seminars held on May 22 and on May 24, 2021. After having recently announced the development of a target enrichment-based, culture free genomic assay for the comprehensive surveillance of AMR pathogens, Dr....

HOUSTON, June 28, 2021 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it has entered into a license agreement with the University of North Carolina Lineberger Comprehensive Cancer Center (UNC Lineberger) and Massachusetts General Hospital (Mass General) covering certain intellectual property and technology rights regarding the company’s CaspaCIDe (inducible caspase-9, or iC9) safety switch and related technologies, and the use of rimiducid. CaspaCIDe may facilitate the use of cell therapies where cytokine release syndrome and neurotoxicities have been observed, in the pursuit of novel targets with on-target/off-tumor safety concerns, and in conjunction with next generation higher potency cell therapy constructs. This...